Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aquivia Health vs Unique Physique

Aquivia Health
Graded #81

Higher grade

vs+10.600000000000001
Unique Physique
Graded #290

Lower grade

The verdict

Aquivia Health takes it — 72.2/100 to 61.6/100.

Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAquivia Health +8
86
78
Dose & formulationAquivia Health +24
85
61
Clinical oversightAquivia Health +2
64
62
Labs & monitoringAquivia Health +3
53
50
FulfillmentAquivia Health +24
71
47
Contract termsEven
55
55
Aquivia Health · left barUnique Physique · right bar

The numbers

MetricAquivia HealthUnique Physique
WeighScore72.2/10061.6/100
GradeCC
Scorecard rank#81#290
Semaglutide$149/moNot disclosed
Tirzepatide$179/moNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Aquivia Health

Graded #81 · C

Strengths

  • Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
  • Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
  • Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
  • Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
  • Self-pay model with no insurance required and no separate consultation fee

Where it loses points

  • No public list of states served — you must complete intake to learn if your state qualifies
  • No named 503A compounding pharmacy partner, limiting licensure verification
  • No LegitScript, PCAB, or BBB trust badges visible
  • Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Unique Physique

Graded #290 · C

Strengths

  • Legal entity disclosed (Unique Physique, LLC) with Louisiana governing law — better than opaque DTC competitors
  • Named medical director (Reena John, DO) — uncommon at this price tier
  • Brick-and-mortar clinic in Baton Rouge, LA offers an in-person option vs ship-only competitors
  • Transparent two-tier flat pricing ($195/mo and $325/mo) — no dose-escalation surprises
  • Brand-name routing option ($25/mo) sends an Rx to your own pharmacy for Wegovy/Zepbound/Ozempic/Mounjaro

Where it loses points

  • GLP-1 drug molecules aren't named on the pricing or service pages — you can't confirm what the $195/mo and $325/mo plans contain without calling
  • Pharmacy partner not named — can't verify licensure or 503A vs 503B status
  • No FDA compounded-medication disclaimer on any audited page
  • States served not listed — only "licensed clinicians in the patient's state"
  • Non-refundable per the Terms; medication not picked up within 60 days is discarded with no refund

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard